Dataset Information

In vitro virucidal activity of the theaflavin-concentrated tea extract TY-1 against influenza A virus.

ABSTRACT: The annual spread of influenza A virus (IAV) infection is a global concern. We examined the IAV-inactivating potential of theaflavin-concentrated tea extract TY-1, which contains abundant polyphenols, including concentrated theaflavins and catechins. TY-1 exhibited concentration- and time-dependent virucidal activity against IAV. Specifically, 5.0 mg/mL TY-1 induced a 1.33 and ≥ 5.17 log₁₀ 50% tissue culture infective dose/mL reduction of the viral titer compared with dextrin as the diluent control within 30 min and 6 h reaction time, respectively. The high virucidal activity of TY-1 was attributed to the combined additive activities of multiple virucidal components, including theaflavins, which led to an investigation of the virucidal mechanism of action of TY-1. Western blotting revealed that TY-1 treatment reduced the band intensity of hemagglutinin and induced the appearance of additional high molecular mass bands/ladders. In addition, TY-1 treatment also reduced the band intensity of neuraminidase (NA). A hemagglutination assay revealed that TY-1 reduced hemagglutination activity, and an NA assay revealed reduced NA activity. These results indicated that TY-1 caused structural abnormalities in IAV spike proteins, possibly leading to their destruction. Reverse transcription polymerase chain reaction (PCR) targeting the IAV genome and electron microscopic observation of viral particles revealed that upon application of TY-1, the PCR products dissipated, which indicates that TY-1 destroyed the IAV genome, and the number of viral particles reduced. Overall, TY-1 exhibited multiple modes of IAV-inactivating activity. Our findings support the possible future practical use of TY-1 as a virucidal supplemental agent that can contribute to IAV infection control.

SUBMITTER: Mohamed IMA

PROVIDER: S-EPMC8456404 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:The defense against influenza virus (IV) infections still poses a series of challenges. The current antiviral arsenal against influenza viruses is in fact limited; therefore, the development of new anti-influenza strategies effective against antigenically different viruses is an urgent priority. Bioactive compounds derived from medicinal plants and fruits may provide a natural source of candidates for such broad-spectrum antivirals. In this regard, cranberry (Vaccinium macrocarpon Aiton) extracts on the basis of their recognized anti-adhesive activities against bacteria, may provide potential compounds able to prevent viral attachment to target cells. Nevertheless, only few studies have so far investigated the possible use of cranberry extracts as an antiviral tool. This study focuses on the suitability of a cranberry extract as a direct-acting anti-influenza compound. We show that the novel cranberry extract Oximacro® inhibits influenza A and B viruses (IAV, IBV) replication in vitro because of its high content of A-type proanthocyanidins (PAC-A) dimers and trimers. Mechanistic studies revealed that Oximacro® prevents attachment and entry of IAV and IBV into target cells and exerts a virucidal activity. Oximacro® was observed to interact with the ectodomain of viral hemagglutinin (HA) glycoprotein, thus suggesting the interference with HA functions and a consequent loss of infectivity of IV particles. Fluorescence spectroscopy revealed a reduction in the intrinsic fluorescence of HA protein after incubation with purified dimeric PAC-A (PAC-A2), thus confirming a direct interaction between HA and Oximacro® PAC-A2. In silico docking simulations further supported the in vitro results and indicated that among the different components of the Oximacro® chemical profile, PAC-A2 exhibited the best binding propensity with an affinity below 10 nM. The role of PAC-A2 in the anti-IV activity of Oximacro® was eventually confirmed by the observation that it prevented IAV and IVB replication and caused the loss of infectivity of IV particles, thus indicating PAC-A2 as the major active component of Oximacro®. As a whole, these results suggest Oximacro® as a potential candidate to create novel antiviral agents of natural origin for the prevention of IV infections.

Dataset Information

In vitro virucidal activity of the theaflavin-concentrated tea extract TY-1 against influenza A virus.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets